Protibea Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2025-08-18.
Protibea Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on August 18, 2025. The filing reports $200K sold. Its industry group is Other Health Care. It names William Chamberlin (CEO of the Issuer), Jim Moriarty (Executive Officer, Director), Yu Ge (Director) (SEC Form D, August 18, 2025).
Is this your company?
Sell to companies like Protibea Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-08-18 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Protibea Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Protibea Therapeutics, Inc., from the filings we hold.
Other Health Care raises by companies based in Texas, filed in August 2025, largest first.
Get an email when Protibea Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Protibea Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Protibea Therapeutics, Inc. →Get the full cited report on Protibea Therapeutics, Inc.
What the filing shows about Protibea Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Protibea Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Protibea Therapeutics, Inc.'s address as 1108 Legacy Crossing, Georgetown, TX 78628.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Protibea Therapeutics, Inc. See pricing
Protibea Therapeutics, Inc. is a registered filer with the SEC (CIK 1864104) and has filed since 2025-08-18. 1 filing is on record, the latest on 2025-08-18.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Protibea Therapeutics, Inc.'s Form D of 2025-08-18 names William Chamberlin, Jim Moriarty, Yu Ge and 1 more as its officers, directors or promoters.
Its new offerings report $200K sold across 1 offering, as its own filings state.
Trailing twelve months. 869 filings in Other Health Care, totalled by week.
On the filing as: Executive Officer, Director.
William Chamberlin is named as Ceo of the Issuer on the Form D that Protibea Therapeutics, Inc. filed with the SEC on 18 August 2025, one of 4 people that filing names.
Jim Moriarty is named as Executive Officer and Director on the Form D that Protibea Therapeutics, Inc. filed with the SEC on 18 August 2025, one of 4 people that filing names.
Yu Ge is named as Director on the Form D that Protibea Therapeutics, Inc. filed with the SEC on 18 August 2025, one of 4 people that filing names.
Harry Oken is named as Director on the Form D that Protibea Therapeutics, Inc. filed with the SEC on 18 August 2025, one of 4 people that filing names.
4 people named on the filing — 2 holding an executive role and 2 as directors only.
Named as of the 2025-08-18 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Protibea Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Protibea Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Protibea Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Protibea Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Protibea Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Protibea Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Health care raises in Austin
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/protibea-therapeutics-inc-form-d-25000001